Exclusive online education for obstetricians and other healthcare professionals involved in childbirth.

Dr Rikke Bek Helmig, Senior Consultant Obstetrician, PhD.

(Denmark)

Prof Jodie Dodd

Obstetrician

(Australia)

Dr Lone Hvidman, Consultant Obstetrician MD, Ph.D.

(Denmark)

CARDIOLOGY EDUCATION

Introducing a low dose oral misoprostol tablet for induction of labour

 - a change to Australian practice?

Exclusive educational event for obstetricians and other healthcare professionals involved in childbirth.

Introducing a low dose oral misoprostol tablet for induction of labour – 

a change in the Australian practice?

Dr Rikke Bek Helmig, Senior Consultant Obstetrician, PhD.

(Denmark)

Prof Jodie Dodd

Obstetrician

(Australia)

Dr Lone Hvidman, Consultant Obstetrician MD, Ph.D.

(Denmark)

CARDIOLOGY EDUCATION

Event countdown

Countdown

8:05 – 8:25 pm

Live panel discussion and audience Q&A

7:50 – 8:05 pm

Adoption of a new oral method of induction in the Australian clinical practice: what changes are needed? - Professor Jodie Dodd

7:20 – 7:50 pm

First-hand experiences with ANGUSTA® (misoprostol) in Europe: a practical approach - Dr Rikke Bek Helmig and Dr Lone Hvidman

7:05 – 7:20 pm

Overview of key clinical data of ANGUSTA® (misoprostol) - Professor Jodie Dodd

7:00 – 7:05 pm

Welcome and introduction - Professor Jodie Dodd (Chair)

8:25 – 8:30 pm

Close & Summary - Professor Jodie Dodd (Chair)

Agenda

4

Live panel discussion and audience Q&A

3

Adoption of a new oral method of induction in the Australian clinical practice: what changes are needed? - Professor Jodie Dodd

2

First-hand experiences with ANGUSTA® (misoprostol) in Europe: a practical approach - Dr Rikke Bek Helmig and Dr Lone Hvidman

1

Overview of key clinical data of ANGUSTA® (misoprostol) - Professor Jodie Dodd

What this education covers

This educational webinar aims to update Obstetricians and other specialists involved in maternity care regarding the introduction of a new oral method of labour induction (ANGUSTA® - misoprostol)¹ in the Australian practice.


A summary of the comprehensive clinical data on the use of low dose oral misoprostol in induction of labour will be followed by presentation of first-hand experience in Europe since ANGUSTA® was first introduced back in 2017². We will explore practical approaches associated with the introduction of ANGUSTA® including dosing regimens, hospital protocols, use in special populations amongst other aspects relevant to prescribing.


To bring the conversation back to our local context, we will finish the webinar by exploring what the adoption of the new oral method of induction means for Australian clinicians, what the impact of the recent update to the RANZCOG guidelines for 'Use of Prostaglandins for induction of labour'³ are and what changes are likely needed in the Australian clinical practice.

Introducing a low dose oral misoprostol tablet
for induction of labour –
a change to Australian practice?

Presenters

Professor of obstetrics and gynaecology; maternal fetal medicine specialist
View profile
Professor Jodie Dodd is a full-time clinical academic Obstetrician, and Maternal Fetal Medicine (MFM) Specialist. She is the Medical Director of Women’s and Babies (WABS) Division, current NHMRC Investigator Fellow at the Women’s and Children’s Hospital (WCH), and Head of Department of Obstetrics and Gynaecology, University of Adelaide. She is a Fellow of the Australian Academy of Health and Medical Sciences.

Her research program evaluates healthcare interventions in pregnancy and prior to conception to improve health outcomes for women and their babies, involving all clinical aspects of obstetric and MFM clinical practice, including induction of labour, preterm birth prevention, timing of birth for women with a twin pregnancy, care for women with a prior caesarean section in their subsequent birth, the role of MCA Doppler in women whose pregnancy is affected by red cell alloimmunidation, and dietary and lifestyle interventions in pregnant women and prior to conception. Her PhD involved the completion of a large, randomised trial comparing oral misoprostol solution with vaginal dinoprostone gel for induction of labour at term. She has received continuous NHMRC Fellowship support (2006-2025), and approximately $52 million in competitive research funding.

Prof Jodie Dodd (Australia)

Department Obstetrics & Gynecology, Aarhus University Hospital, Skejby
View profile
Dr Helmig is a Consultant Obstetrician at the Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby (Denmark) since 2008.

Her main interest in Obstetrics is pre-term delivery, both in the clinical setting and in different scientific studies; she also has a particular interest in infections and preterm deliveries. She obtained her PhD in 1995, where she studied in vitro Group B Streptococci (GBS) and pre-term delivery. She has continued working with different issues regarding GBS in pregnancy and during labour.

In the clinical setting, her focus is on safety both during pregnancy, during induction of labour and at delivery, as well as in the post-partum period.

Dr Rikke Bek Helmig (Denmark)

Department Obstetrics & Gynaecology, Aarhus University Hospital, Skejby
View profile
Dr Hvidman is a Consultant Obstetrician at the department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, Denmark since 1995.

She is the head of the steering group for Danish Obstetric Guidelines.

Her main interests are Obstetric Emergencies, Simulation in Obstetrics and Induction of labour - clinically as well as scientific.

Dr Lone Hvidman (Denmark)

5

Identify strategies to minimise infection during flood-borne outbreaks and steps that could be taken in primary care to better protect the community.


1

Recall the symptoms, diagnosis and mode of transmission for the Japanese Encephalitis Virus (JEV).

By the end of this activity, you will be able to:

3

Highlight the importance of JEV vaccination for travellers going overseas and in local community areas where flood-borne outbreaks regularly occur.


2

Identify key causes of historical JEV outbreaks, where in Australia this virus is most prevalent and why.

4

Review ATAGI recommendations for vaccine eligibility and indications across the different age groups and patient conditions



Learning Outcomes

  • - please select -
  • Obstetrics consultant
  • Obstetrics trainee/registrar
  • Gynaecologist
  • Hospital Pharmacist
  • Other specialist including GP
  • Midwife/Nurse
  • Other
Thank you for registering to attend! Please keep an eye out for emails relating to the event.
The Provider of this activity is Praxhub. The details provided by you will be used for the purpose of facilitating your attendance at this activity and creating your Praxhub registration to enable your access to this and other on-demand content. If you have questions regarding the collection or use of your information, please contact privacy@praxhub.com. 


Please enter your details to attend.  

Once completed, please check your email for reminders.

* indicates required field

Register to attend

To access hundreds of quality CPD training courses, simply join Praxhub's online medical community

INDICATION: induction of labour. CONTRAINDICATIONS: when labour has started, suspicion or evidence of foetal compromise prior to induction, when oxytocic drugs and/or other labour induction agents are being given, suspicion or evidence of uterine scar resulting from previous uterine or cervical surgery, e.g. caesarean delivery, uterine abnormality (e.g. bicornuate uterus) preventing vaginal delivery, placenta praevia or unexplained vaginal bleeding after 24 weeks gestation with this pregnancy, foetal malpresentation, contraindicating vaginal delivery, kidney failure (GFR<15ml/min/1.73m2), hypersensitivity to active substance or excipients.
SPECIAL WARNINGS AND PRECAUTIONS: should only be administered by trained obstetric personnel in a hospital setting where facilities for continuous foetal and uterine monitoring is available. Cervix should be assessed carefully, only recommended for use in patients with unfavourable cervix i.e. mBS <=6. Can cause excessive uterine stimulation. Pre-eclampsia, gestation < 37 weeks, membrane rupture > 48 hours prior, multiparity. Use in pregnancy: Pregnancy Category X. Use in lactation: breast-feeding can start immediately after birth. Use in hepatic and renal impairment: lower dose and/or prolonged dosing intervals should be considered. Paediatric use: no studies in women <18 years.
INTERACTIONS WITH OTHER MEDICINES: No interaction studies.
ADVERSE EFFECTS: Nausea, vomiting, diarrhoea, meconium stain, postpartum haemorrhage, uterine hyperstimulation / foetal heart rate abnormal, chills, pyrexia, low apgar score,.
DOSAGE AND ADMINISTRATION: oral, 25 micrograms 2 hourly, or 50 micrograms 4 hourly. Maximum dose is 200 micrograms over 24 hours.
PRESENTATION AND STORAGE CONDITIONS: White, uncoated oval shaped tablet, 7.5 x 4.5 mm, score line one side, plain other side. Score line not for breaking tablet. Packs of 8. Store Below 25 °C.
NAME AND ADDRESS OF THE SPONSOR: Australia: Norgine Pty Limited, Suite 3.01, Building A, 20 Rodborough Road, Frenchs Forest NSW 2086. Telephone: 1800 766 936.
POISON SCHEDULE OF THE MEDICINE: Schedule S4 – Prescription Only Medicine
BEFORE PRESCRIBING, PLEASE REVIEW PRODUCT INFORMATION. Product Information is available from Norgine Pty Ltd on 1800 766 936


AU-OBS-ANG-2300032. Date of preparation: June 2023



Images featured on this page are for illustrative purposes only. Any persons depicted in these images are models and do not use or personally endorse any Norgine products. 

MINIMUM PRODUCT INFORMATION: ANGUSTA (MISOPROSTOL)